BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Chubb
AstraZeneca
Daiichi Sankyo
Colorcon
Fuji
Julphar
Cipla
Medtronic
Merck

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,238,695

« Back to Dashboard

Which drugs does patent 6,238,695 protect, and when does it expire?

Patent 6,238,695 protects SUSTIVA and is included in one NDA.

Protection for SUSTIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-two patent family members in twenty-six countries.
Summary for Patent: 6,238,695
Title: Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
Abstract:The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.
Inventor(s): Makooi-Morehead; William T. (Wallingford, PA), Buehler; John D. (Ambler, PA), Landmann; Brian R. (Hoboken, NJ)
Assignee: DuPont Pharmaceuticals Company (Wilmington, DE)
Application Number:09/286,902
Patent Claim Types:
see list of patent claims
Dosage form; Formulation; Process; Composition; Use;

Drugs Protected by US Patent 6,238,695

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-001 Sep 17, 1998 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-002 Sep 17, 1998 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,238,695

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,555,133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,238,695

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia 14612000 ➤ Subscribe
Slovenia 1067936 ➤ Subscribe
Portugal 1067936 ➤ Subscribe
Poland 194309 ➤ Subscribe
Poland 343421 ➤ Subscribe
New Zealand 507566 ➤ Subscribe
Norway 325824 ➤ Subscribe
Norway 20005043 ➤ Subscribe
Japan 2002510634 ➤ Subscribe
Israel 138078 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Teva
Accenture
McKinsey
Daiichi Sankyo
Julphar
Dow
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot